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Transporters are ubiquitous proteins mediating the translocation of solutes across cell
membranes, a biological process involved in nutrition, signaling, neurotransmission, cell
communication and drug uptake or efflux. Similarly to enzymes, most transporters
have a single substrate binding-site and thus their activity follows Michaelis-Menten
kinetics. Substrate binding elicits a series of structural changes, which produce a
transporter conformer open toward the side opposite to the one from where the
substrate was originally bound. This mechanism, involving alternate outward- and
inward-facing transporter conformers, has gained significant support from structural,
genetic, biochemical and biophysical approaches. Most transporters are specific for a given
substrate or a group of substrates with similar chemical structure, but substrate specificity
and/or affinity can vary dramatically, even among members of a transporter family that
show high overall amino acid sequence and structural similarity. The current view is that
transporter substrate affinity or specificity is determined by a small number of interactions
a given solute can make within a specific binding site. However, genetic, biochemical and
in silicomodeling studies with the purine transporter UapA of the filamentous ascomycete
Aspergillus nidulans have challenged this dogma. This review highlights results leading
to a novel concept, stating that substrate specificity, but also transport kinetics and
transporter turnover, are determined by subtle intramolecular interactions between a
major substrate binding site and independent outward- or cytoplasmically-facing gating
domains, analogous to those present in channels. This concept is supported by recent
structural evidence from several, phylogenetically and functionally distinct transporter
families. The significance of this concept is discussed in relationship to the role and
potential exploitation of transporters in drug action.
Keywords: drug transporters, genetic, model systems, Aspergillus nidulans, crystal structure,
endocytosis/turnover, atypical kinetics
THE DISTINCTION OF CHANNELS AND TRANSPORTERS
Transporters, permeases, carriers, exchangers, pumps or efflux
proteins, facilitators, channels or pores, are all terms used for
transmembrane proteins which mediate the transport of solutes,
metabolites, drugs, xenobiotics or ions across all kinds of cell
membranes, but mostly across the plasma membrane. These
terms are rather confusing to the non-specialists, so for the
present review, I would like to make a simple but important con-
ceptual distinction between transporters and channels (depicted
in Figure 1). A comprehensive classification system for mem-
brane transport proteins, known as the Transporter Classification
(TC) system, analogous to the Enzyme Commission (EC) sys-
tem, can be found in http://www.tcdb.org/ (Saier et al., 2014). For
recent general reviews highlighting differences and similarities in
transporters and channels, see Gouaux and Mackinnon (2005),
Khalili-Araghi et al. (2009), Krishnamurthy et al. (2009), Conde
et al. (2010), Sciara and Mancia (2012).
Transporters (or permeases or carriers) are polytopic trans-
membrane proteins that function as topological enzymes, that is,
they catalyze the translocation of substrates from one side (Greek:
topos) of the membrane to the other. They comprise a single
major substrate-binding site interacting specifically with a sin-
gle substrate molecule in each transport cycle. Consequently they
are characterized, in most cases, with Michaelis-Menten kinetics,
with measurable substrate affinity, inhibition or dissociation con-
stants (Km, Ki, Kd) and transport capacities or rates (V or Vm).
Substrate binding elicits conformational changes, which even-
tually produce a transporter conformer open to the opposite
side from the one from where the substrate originally bound. In
other words, transporters do not contain a continuous open pore
accessible from both sides of a membrane. This “rocking-switch”
mechanism (Kaback et al., 2011), implicating alternate outward-
and inward-facing transporter conformers, has gained signifi-
cant support from structural, genetic, biochemical or biophysical
approaches (see later). Transporters can catalyze the transloca-
tion of 102-105 molecules/s and in most cases seem to operate as
monomeric functional units made of several (frequently 10–14)
transmembrane, mostly α-helical, segments (TMS), well packed
between hydrophilic cytoplasmic or extracellular termini. The
TMS, which are linked by hydrophilic loops of different lengths
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FIGURE 1 | Transporters vs. Channels. Left: A transporter undergoes a
major “rocking-switch” conformational alteration from an outward- to an
inward-facing topology elicited by the binding of a substrate molecule
(shown as a yellow hexagon) to specific residues within a substrate-binding
pocket located deep in the transporter body at the plane of the plasma
membrane. Substrate molecules can be translocated either uphill or
downhill of their concentration gradients, depending on the whether the
transporter is a secondary active transporter (symporter or antiporter) or a
facilitator. The cartoon depicts a symporter, where substrate binding and/or
translocation necessitate cation (H+ or Na+, shown as green stars) binding
and transport downhill their concentration gradient. In antiporters, substrate
uptake is exchanged with export of another metabolite or cations (e.g., K+
or Ca2+). During each transport cycle, the bound substrate molecule is
never exposed to both sides of the membrane simultaneously. Transporters
obey Michaelis-Menten kinetics resembling enzymes, albeit catalyzing a
topological rather than a chemical reaction. Most transporters are
monomers made of several usually 10–14 transmembrane α-helical,
segments (TMS). Right: A channel potentially forms a continuous pore but
in most cases this pore is restricted by so called selectivity filters and
controlled by gating domains or gates (shown in red). Once activated or
open, a channel allows continuous translocation of several substrate
molecules (shown as green stars), which are mostly ions or small polar
compounds, from both sides of the membrane simultaneously. A channel
can only mediate facilitated diffusion of substrate molecules down their
concentration gradients. Most channels function as homo-oligomers made
by 2 or more, mostly α-helical, subunits.
depending on the transporter family, host the amino acid residues
that interact with substrates or catalyze intra-helical interactions
associated with the dynamic translocation of substrates. The
hydrophilic loops linking TMS can also play a role in substrate
recognition and transport, while in eukaryotes the hydrophilic
termini have major roles in the post-translational regulation of
transporter trafficking, endocytosis and vacuolar turnover (see
later). Transporters can function as facilitators (substrate trans-
port down a concentration gradient), active transporters (sub-
strate transport against a concentration gradient coupled with
ATP hydrolysis or most commonly with the symport or antiport
of H+, Na+ or other ions), or exchangers (antiporters) of dif-
ferent substrates translocated in opposite directions. Substrates
of transporters can be all kinds of natural metabolites, including
lipids, xenobiotics, antibiotics or drugs. In fact, very few natu-
ral molecules (e.g., ethanol and some small gases) can efficiently
cross the plasma membrane without the need of a transporter.
Thus, it becomes apparent that antibiotic and drug action is abso-
lutely dependent on relevant transporters, which can mediate
efficient uptake or efflux of these chemicals. However, while we
know much on the action of transporter pumping out drugs and
leading to multidrug or pleiotropic drug resistance in cancer cells
and resistant microbial pathogens (Niero et al., 2014; Paul and
Moye-Rowley, 2014; Sun et al., 2014), we know very little on how
drugs are taken up by target cells.
Channels (or pores) translocate mostly ions or some small
solutes (e.g., water, urea, ammonium or glycerol) and are con-
sidered to have a very different mechanism of action compared
to transporters, also reflected in a different structure. Similarly
to transporters, most channels are made by several, mostly α-
helical, TMSs (with the prominent exception of some porins in
the bacterial outer membrane which are formed by β-sheets),
but in most cases their functional unit is a homo-oligomer made
by association of 2 or more subunits. Channels potentially form
a continuous pore, commonly in the interphase of different
subunits, but inmost cases this pore is restricted by so called selec-
tivity filters and controlled by gating domains or gates. Selectivity
filters are narrow parts of the pore, the size and charge of which
is adapted for a specific ion. Gates can exist toward both sides of
the membrane and correspond to dynamic domains that open or
close in response to a chemical signal. In contrast to transporters,
a channel can be open at both sides of a membrane simultane-
ously. When a channel becomes open one or more ions enter
the channel pore and flow rapidly to the other side of the mem-
brane, downstream the concentration gradient(s). Thus, channels
function only as facilitators, are much faster (up to 108 ions/s)
than transporters, and may lead to the generation of electric
currents when translocating charged ions that alter the cellular
electrostatic status.
Transporters and channels are ubiquitously involved in cell
nutrition, homeostasis, detoxification, stress response, but also
in signaling and neurotransmission. Their biological impor-
tance is reflected by the observation that all known genomes
include at least 5–15% genes coding for transport pro-
teins (http://www.membranetransport.org/). Among the cham-
pions of transporters are most free-living bacteria, fungi,
and plants, whereas channels are more abundant in meta-
zoa. The importance of transport proteins is also reflected
in more than 60 human genetic diseases caused by the mal-
functioning of transporters and channels (e.g., Cystic fibrosis,
Menkes/Wilsons disease, neurodegeneration, amyotrophic lat-
eral sclerosis, Fanconi-Bickel syndrome, Non-insulin-dependent
diabetes, etc.) (http://www.tcdb.org/disease_explore.php). As
already mentioned above, transporters, unlike channels, are also
key mediators of drug and antibiotic action. The present review
has as its main goal to highlight novel findings, somehow
neglected in the field of pharmacology, on the mechanism of
transporter functioning, which I believe are essential to make a
systematic and rational use of transporters as unique tools to
develop novel pharmacological approaches.
DRUG ACTION AND THE POTENTIAL ROLE OF
TRANSPORTERS
Most present day drugs are empirically selected based on their
efficiency against the primary symptoms of an infection or dis-
ease. In the great majority of cases where a drug needs to cross
the plasma membrane to exert its activity, we know very little
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on how the drug enters the cell. Several of the current drugs
are hydrophobic compounds that enter the cell, very proba-
bly, by slow non-facilitated diffusion through the lipid bilayer
of plasma membrane. Some drugs are administered enclosed in
liposomes, so that they enter the cell through fusion of lipo-
somes and plasma membranes. Still, a great number of other
drugs enter cells through unknown transporters or facilitators
(Kell et al., 2011, 2013; Lanthaler et al., 2011). A fact arising from
the above observations is that currently used drugs act against
target and non-target cells non-specifically. To develop more effi-
cient pharmacological approaches we need, ideally, to use drugs
taken up by specific transporters expressed solely in target cells.
This becomes a major challenge specifically when the target is a
eukaryotic cell, such as cancer cells or fungi and protozoans. Some
drugs have been successfully targeted to cancer cells through the
action of specific transporters, such as the peptide transporter
PepT1 (Nakanishi et al., 1997, 2000) or the glucose transporters
GLUT1-5 and SGLT1-3 (Rask-Andersen et al., 2014). However,
still most antifungal, antiprotozoan or anticancer drugs used
today have not been designed to distinguish between the trans-
porters of target and non-target cells and thus may be taken up
non-specifically.
Some present day drugs do not need to cross the plasma mem-
brane to act, but rather target essential plasma membrane com-
ponents, basically transporters, channels or receptors (Hamman
et al., 2007; Kell et al., 2013). Transporters, being the most abun-
dant of these classes of transmembrane proteins, constitute a
promising target for specific drug action. ABC-type transporters,
which are involved in the efflux of drugs and xenobiotics in cancer
cells and resistant microbial pathogens, are among the first to be
recognized as ideal drug targets (Choi and Yu, 2014; Niero et al.,
2014; Paul and Moye-Rowley, 2014; Sun et al., 2014). However,
still little has been achieved in pharmacotherapy through their
inhibition. The P-glycoprotein (MDR1), which is the best-studied
member of the ABC transporter superfamily, has only recently
been exploited for drug development (Zhang and Li, 2013; Saneja
et al., 2014). Of the P-type ATPases, both the Na+/K+-ATPase and
the H+/K+-ATPase are blocked by very useful, and widely used,
pharmacological agents (cardiac glycosides and proton pump
inhibitors, respectively (Alexander, 2011). Besides ABC efflux
proteins, transporters involved in the influx of all kinds of solutes
and metabolites (the so called SLC superfamily; He et al., 2009)
are also exploited as possible drug targets (Giacomini et al., 2010).
Inhibitors of the catecholamine transporters (SLC6A) and Na-K-
Cl or Na-Cl symporters (SLC12A) are highly prescribed as antide-
pressants and diuretics, respectively. The well-studied serotonin
(SERT) and dopamine (DAT) transporters are specific targets of
several currently used antidepressants (Stahl et al., 2013). The
PepT1 transporter involved in oral absorption of di-and tripep-
tides produced by the digestion of ingested proteins has also
become a striking prodrug-designing target recently (Zhang et al.,
2013). Still, additional SLC drug targets are currently in clinical
trials or under development, for the treatment of a wide vari-
ety of diseases and disorders, such as cancer, major depression,
Attention Deficit Hyperactivity, osteoporosis, hypertension, car-
dioprotection, diabetes, constipation and hypercholesterolaemia.
Recently, the International Transporter Consortium (ITC) has
described seven more transporters of particular relevance to drug
development (Giacomini et al., 2010; Huang et al., 2010).
Interestingly however, still most drugs targeting mem-
brane proteins concern receptors, rather than transporters. For
example, while G-protein-coupled receptors (GPCRs) repre-
sent more than one-quarter of drug targets, currently approved
inhibitors of transporters are ten times less (Overington et al.,
2006). This contradicts the higher gene number of transporter
genes compared to genes encoding “druggable” G protein-
coupled receptors (Rask-Andersen et al., 2014). Why is that
so? The answer is a dramatic lack of knowledge on the
molecular and functional details of transporters. Not only
we do not know the structure, function, kinetics or speci-
ficity of most human and microbial transporters, but we also
know very little on the conditions that affect their expres-
sion. Moreover, in order to use transporters either as gate-
ways for targeted drug delivery, or as targets, we need to
know the full complement of transporters in both target and
non-target cells.
TRANSPORTERS IN PATHOGENS AS DRUG GATEWAYS OR
TARGETS
Most bacteria, fungi and protozoa possess hundreds of trans-
porters, some not present in higher eukaryotes (see;http://www.
membranetransport.org/; Ren et al., 2004 and http://www.tcdb.
org/). In addition, even in cases where the host cells and a micro-
bial pathogen possess similar transport activities, these are often
characterized by distinct kinetics and specificity profiles. Thus,
in principle, transporters of microbial pathogens can well be
exploited as specific gateways of antimicrobials. Compatible with
this idea is that today, with the easiness and efficiency of genome
sequencing and the development of powerful reverse genetics
approaches, the systematic characterization of the complete com-
plement of transporters in the most important pathogens is only
a matter of dedicated effort. In such an effort, and especially to
carry out sophisticated reverse genetic approaches and rigorous
biochemical assays, the use of model bacteria, fungi and pro-
tozoa, will constitute a major step. This is necessary as one of
the major problems studying the function and specificity of a
given transporter is the existence of a multitude of transporters
of overlapping specificities in most organisms. Thus, it is prac-
tically impossible to rigorously characterize with simple uptake
assays the kinetics and specificity of a transporter if other similar
transporters are also present. This problem can only be over-
come by studying a single transporter in an appropriate genetic
background lacking any other functionally related transporter.
Such strains can be easily constructed and tested by combining
multiple gene knock-out mutations in model microbes such as
Escherichia coli, Aspergillus nidulans or Saccharomyces cerevisiae.
Transporters from pathogenic microbes can also be isolated,
expressed and functionally characterized in appropriate strains of
model relatives, as for example has been the case for a number of
A. fumigatus and Candida albicans purine transporters studied in
A. nidulans or S. cerevisiae (examples in Goudela et al., 2006, 2008;
Keniya et al., 2013), or some protozoan transporters studied in
S. cerevisiae (Burchmore et al., 2003; Natto et al., 2005; Al-Salabi
et al., 2007; Papageorgiou et al., 2008b).
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Once transporters of model or pathogenic microorganisms are
genetically, biochemically and physiologically characterized, the
next step will be to identify the most promising among them in
respect to antimicrobial drug recognition and uptake. Selected
transporters based on their specificity profiles and preliminary
in vivo assays can be tested for the translocation of existing
powerful antimicrobials or novel drugs, which can be designed
or screened from chemical libraries through rational or semi-
rational approaches (Zhu et al., 2013). These later approaches will
necessitate deep knowledge on the molecular details underlying
transporter-substrate interactions and the mechanisms of sub-
strate translocation. Such knowledge should be obtained through
crystal structures, homology modeling, docking approaches and
Molecular Dynamics (MD), but also by extensive mutational and
biochemical analyses uniquely feasible in model microorganisms.
An alternative to the exploitation of microbial transporters
as drug gateways is their use as drug targets in cases where
transporters prove essential for survival or virulence. Recently,
such a case was exemplified by Borrelia burgdorferi, the causative
agent of Lyme disease (Samuels and Radolf, 2010; Jain et al.,
2012). Borrelia is transmitted to humans by the bite of infected
ticks belonging to a few species of the genus Ixodes. The infec-
tion is usually eliminated by antibiotics, only if treated early
but some individuals do not respond to antibiotic treatment.
Moreover, present day vaccines present autoimmune side effects
and are expensive. An alternative highly targeted pharmacological
approach can now be developed based on the fact that B. burgdor-
feri lacks the enzymes required for de novo synthesis of purines
and therefore its life cycle and virulence depends on two purine
transporters of the NAT family (see later), named BBB22 and
BBB23. This is supported by the observation that B. burgdor-
feri lacking bbb22-23 was non-infectious in mice (Jain et al.,
2012). Thus, any compound specifically inhibiting the BBB22/23
transporters might potentially serve as a highly specific drug for
treating Lyme disease. Importantly, the fact that BBB22/23 trans-
porters belong to a NAT subfamily, called AzgA (Cecchetto et al.,
2004; Krypotou et al., 2014), absent in humans, enhances the pre-
diction that BBB22/23-specific drugs might well not be associated
with undesirable side effects.
APPROACHING TRANSPORTER STRUCTURE-FUNCTION
RELATIONSHIPS
Until some years ago, most of what we knew on the func-
tion of transporters has come through genetic and biochemical
approaches mostly performed with the lactose permease of E. coli
(LacY) and a handful of other transporters, the majority of which
were of bacterial origin (for LacY reviews see Kaback et al., 1993,
1994, 2001; Kaback and Wu, 1997). The reason for this is directly
related to the low expression level, hydrophobic nature, big size
and transmembrane topology of transporters. Even today, trans-
porters cannot be studied by biophysical or structural approaches
in their natural membrane environment. The use of deter-
gents during purification for crystallographic or other biophysical
methods, or reconstitution in proteoliposomes for functional
assays, do not take into account the significant role of specific
lipid species in transporter folding, functioning or turnover. This
problem becomes even more serious when it concerns eukaryotic
transporters, where lipids play additional regulatory roles related
to membrane trafficking and PM expression of a transporter.
Because of these technical problems, Kaback working on LacY,
and a handful of other scientists studying other transporters, ini-
tiated rational genetic and biochemical approaches, combined
with simple radiolabeled substrate uptake assays in intact bac-
teria or other easily manipulated cells, such as fungi, protozoa,
red blood cells, oocytes or cultured mammalian cell lines. The
work with LacY is by far the most impressive (see reviews Kaback
et al., 1993, 1994, 1997). Each of the 417 aminoacyl side-chains
in LacY has been mutated and remarkably, fewer than 10 residues
located in TMS4, TMS5, TMS7, TMS8, TMS9, and TMS10, were
shown to be irreplaceable for active lactose transport (Frillingos
et al., 1998). The employment of Cys-scanning mutagenesis and
its downstream applications have proved to be a breakthrough
tool in assigning functional or structural roles to specific residues
in transporters (Frillingos et al., 1998). Thus, even before the
appearance of the first crystal structure of any transporter in early
2000s, Kaback and co-workers have proposed a theoretical model
of the topological arrangement of transmembrane domains in
LacY, provided rigorous evidence on which amino acid residues
are involved in substrate and H+ binding and translocation, and
proposed mechanism for transport catalysis.
In this mechanism, the substrate and the H+ ion interact
within a single binding pocket accessible in an outward-
facing conformation of the transporter, and this binding subse-
quently promotes a dramatic conformational change leading to
a cytoplasm-facing transporter capable of liberating the substrate
and the H+ ion into the cell. This “rocker-switch” mechanism,
which implies that transporters are never accessible to substrates
from both sides of the membrane, but they rather alternate
between two conformers, has been subsequently supported by
numerous kinetic, biochemical and biophysical studies not only
for LacY (Abramson et al., 2004; Kaback et al., 2011), but also
for several other transporters (Forrest et al., 2011; Shi, 2013;
Penmatsa and Gouaux, 2014; see also later).
The “rocker-switch” mechanism predicts that mutations
affecting substrate binding affinities or substrate specificity,
should affect residues interacting with substrates directly or indi-
rectly. Mutational and second-site suppressor analyses have sup-
ported that idea in general (Cain et al., 2000; Johnson et al.,
2001; Green et al., 2003). In some specific cases however, muta-
tions modifying transporter specificity in LacY (Naftalin, 2010)
or other transporters (see later) could not fit with the simple
“rocker-switch” alternating model. This issue will be discussed in
the next section of this review.
In recent years (since 2003), the availability of 2D and
3D structures obtained by EM crystallography and X-ray,
as well as contributions from computational and theoretical
approaches, have greatly enhanced our understanding of trans-
porter structure-function relationships. The first crystal struc-
ture of a secondary active transporter at atomic resolution was
obtained in 2002 (bacterial multidrug efflux transporter AcrB;
Murakami et al., 2002), while LacY was crystallized in 2003
(Abramson et al., 2003). At present there are <50 transporter
structures analyzed at atomic levels of 1.5–3.7 A˙ in total (see
http://blanco.biomol.uci.edu/mpstruc/). Among those, less than
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20 concern ATP-dependent ABC primary active transporters and
the rest are cation symporters, facilitators, antiporters or exchang-
ers. The great majority of transporters consist of 10–14 α-helical
transmembrane segments (TMS) connected via intracellular and
extracellular loops, and cytoplasmic N- and C-terminal regions.
These transporters seem to function as monomers, although
some also form dimers or oligomers. Shorter transporters made
of 3–6 TMS seem to form homo- or hetero-oligomeric func-
tional complexes. Surprisingly, transporters of functionally and
evolutionary distinct protein families with no primary amino acid
sequence similarity and different substrate specificities seem to
exhibit similar folds.
The majority of known transporter structures fall within two
types of folds; the 6+6 of Major Facilitator Superfamily (MFS)
type (Abramson et al., 2004; Kaback et al., 2011; Madej et al.,
2014), and the 5+5 intertwined LeuT/Mhp1 type (Yamashita
et al., 2005; Weyand et al., 2008; Forrest et al., 2011; Shi, 2013;
Penmatsa and Gouaux, 2014). 6+6 or 5+5 depicts the α-helical
transmembrane segments present in each type of transporter fold.
A variation of the 5+5 fold is exemplified by the 7+7 transporters
of the NAT/NCS2 family (Lu et al., 2011; Västermark and Saier,
2014). In fact, several of the 5 + 5 transporters contain 2 or 4 extra
helices, having in total 12 or 14 TMS, but these extra domains
are probably involved in oligomerization, trafficking or turnover,
rather than transport activity (Västermark and Saier, 2014). The
common structural folds found in symporters, facilitators and
antiporters strongly suggest that overall protein architecture does
not dictate the mode of transport. Despite important structural
differences, as for example the site of the major substrate bind-
ing site and the mechanism of transport, all types share some
common themes, such as an apparent two-fold internal struc-
tural symmetry, or the presence of discontinuous membrane
α-helices hosting residues involved in substrate and/or ion bind-
ing, suggesting some common ancestral origins (Forrest et al.,
2011; Krishnamurthy and Gouaux, 2012; Shi, 2013; Penmatsa and
Gouaux, 2014; Västermark and Saier, 2014).
How has the recent boom in transporter crystallography
changed our view on transporter structure-function relation-
ships and the mechanism of transport catalysis? Do residues
found to be responsible for substrate binding or translocation by
purely genetic and biochemical analyses agree with their position
in the crystal structures? Or vice versa, do the models proposed
account for the effects produced by mutation of specific residues?
The answer is generally yes, since in most cases genetics and
biochemistry proved to be in good agreement with structural
studies. A more difficult question to be answered is whether
the alternating conformation “rocker-switch” mechanism is still
valid? The answer to this question is a little more complex and is
discussed below.
What the recent transporter structures tell us is that trans-
porters can be found in a series of interrelated intermediate
conformations and not simply in outward- or inward-facing
topologies. In other words, according to the current model based
on the available structures, a transporter cycles through a set
of defined conformational states providing a unique structural
framework necessary for efficient substrate transport. The princi-
ple of a transport cycle is illustrated in Figure 2. In this model, the
substrate(s) first binds to the empty transporter in the outward
facing conformation, where the binding site is only accessible
from the outer side. This is followed by the closure (or occlusion)
of outer molecular gates to hinder substrate diffusion. The gate
closure is facilitated by the substrate-induced rearrangement of
single amino acid side chains or by the bending of single α-helices,
parts of helices or helical hairpins. The transport cycle then pro-
ceeds by a substantial conformational change from the occluded
(closed) outward-facing to the occluded inward-facing conforma-
tion. During this structural switch the transporter passes through
the intermediate occluded form, where the substrates are inacces-
sibly buried within the protein. This is followed by the opening
of the inner molecular gates thus enabling the release of the
substrates from the transporter protein into the cytosol. The
transport cycle is completed when the transporter switches from
the empty internal form, back to the empty external conforma-
tion, enabling the protein to start a new cycle (Diallinas, 2008;
Forrest and Rudnick, 2009; Reyes et al., 2009; Forrest et al.,
2011; Madej et al., 2012, 2014). In the case of an antiporter, a
single substrate is transported during the conversion from the
occluded outward-facing to the occluded inward-facing confor-
mation, while the co-substrate is transported in the returning
step from the inward to the outward conformation. In summary,
the current idea is that transporters function through a cascade
of conformational alterations, some of which are “small” (gate
closure and opening), some more dramatic (outward to inward
transition of the main translocation trajectory). A rocker-switch
alternating access mechanism, at its basic principles, is thus still
true for both the 6+6 and 5+5/7+7 type transporters.
What is drastically new in this modified conformation-switch
mechanism is the presence of functionally and topologically
independent channel-like gates controlling the selective access
of substrates to the major transport binding site. Thus gates
made a slow and discrete appearance in transporters. This might
have been a surprise to most structural biologists, but not to
geneticists. In 2001, long before crystal structures revealed the
presence of selective gates, their existence has been proposed
through the functional characterization ofmutations affecting the
specificity of a fungal purine transporter. Unfortunately, in our
days, structural biologists or hardcore biochemists seem to “miss”
information coming from simple genetic model systems. This
review wishes to highlight how genetic approaches can be used
to establish the existence of gates in transporters and study their
role in substrate selection, but, unexpectedly, also in transporter
turnover.
CLASSICAL GENETICS PREDICTED THE EXISTENCE OF
GATES AND SHED NEW LIGHT ON THE MOLECULAR BASIS
OF TRANSPORTER SPECIFICITY
UapA is one the best functionally characterized eukaryotic trans-
porters (reviewed in Diallinas and Gournas, 2008; Gournas et al.,
2008). It is a high affinity, high-capacity, H+ symporter spe-
cific for the uptake of uric acid or xanthine in A. nidulans.
UapA has also moderate affinities for some xanthine or uric acid
analogs (e.g., 2- or 6-thio analogs or 3-methylxanthine), includ-
ing the drugs allopurinol or oxypurinol (Goudela et al., 2005).
The uapA gene was identified in the mid 60 s through mutations
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FIGURE 2 | Transporters in action and the role of gates. Accumulating
evidence supports a theoretical trailer of alternating transporter
conformations involving five structurally distinct basic conformations: (1)
outward-facing with extracellular gate open (cytoplasmic gate occluded),
(2) outward-facing with extracellular gate occluded (cytoplasmic gate
remains occluded), (3) intermediate with both gates occluded, (4)
inward-facing with gates occluded, (5) inward-facing with only cytoplasmic
gate open. Gates, shown in red, can be made by a few flexible amino
acids or bigger domains made of parts of α-helices. Starting from (1),
binding of Na+ or H+ (green stars) at the extracellular gate or deeper
into the major substrate-binding pocket, stabilizes the outward-facing
open state, creating a high-affinity substrate-binding site deep in the
transporter body. Substrates (yellow hexagon) might also bind selectively
to the extracellular gate. Following substrate and potentially additional ion
binding, the extracellular gate closes and this closure promotes an
induced-fit transition to the intermediate or inward-facing occluded state.
This transition involves major conformational movements of flexible
α-helices or parts of helices (shown in deep blue). In the inward-facing
state, release of Na+ or H+ stabilizes the opening of the intracellular
gate and triggers substrate release. The empty inward-facing open
transporter can then transit back outward-facing state and, thereby,
complete the transport cycle. The diagram shows a single-step transition
from “inward-open” to “outward-open,” whereas this might take several
intermediate steps. The cartoon depicts a symporter but the same model
can be easily adapted to facilitators and antiporters. This model
essentially combines aspects of the rocker-switch model with channel-like
gating. Genetic, biophysical and computational approaches suggest that
gates can act as secondary transient binding sites of substrates and ions.
leading to resistance to a morphological effect produced by 2-
thioxanthine (Darlington and Scazzocchio, 1967). Mutations in
the promoter of uapA, were probably among the first cis-acting
regulatory mutations isolated and studied in a eukaryote (Arst
and Scazzocchio, 1975). The gene was cloned in 1989 by inser-
tional inactivation and sequenced early in the 90 s (Diallinas
and Scazzocchio, 1989; Gorfinkiel et al., 1993). Since then,
UapA has been extensively studied in respect to transcription
and post-translational regulation in response to physiological
signals, conidiospore germination or asexual development. In
summary, the transcription of the UapA is developmentally
induced early during germination (Amillis et al., 2004), whereas
in mycelia transcript levels are highly regulated in response to
substrate-induction and ammonium repression (Diallinas and
Scazzocchio, 1989; Gorfinkiel et al., 1993). Furthermore, plasma
membrane UapA is finely down-regulated by rapid ubiquitina-
tion, endocytosis and vacuolar turnover, in response to ammo-
nium (Pantazopoulou et al., 2007; Gournas et al., 2010) or
excess substrates (Gournas et al., 2010; Karachaliou et al., 2013)
Interestingly, substrate-elicited endocytosis, unlike ammonium
triggered internalization, depends on the transport activity of
UapA (see later).
In the recent years novel tools have been designed that allowed
the direct and rigorous study of the function of UapA. These
tools were based on four important technical innovations: (i)
the development of rapid uptake assays using germinated coni-
diospores of A. nidulans, which avoided technical difficulties
associated with the use ofmycelia (Krypotou andDiallinas, 2014),
(ii) the genetic identification of all major A. nidulans transporters
involved in purine, pyrimidine or nucleoside transport, which
eventually led to the construction of appropriate null strains, per-
mitting the study of a specific transporter in a “clean” genetic
background devoid of similar transporters (Pantazopoulou and
Diallinas, 2006; Diallinas, 2008; Krypotou and Diallinas, 2014),
(iii) the development of very efficient reverse genetic approaches
in A. nidulans, which permitted the rigorous study of any mutant
transporter version expressed from it genetic locus (Nayak et al.,
2006; Szewczyk et al., 2006), and (iv) the employment of in vivo
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fluorescent microscopy approaches using GFP- or RFP-tagged
functional transporters, which directly allowed the classification
of transporter mutants in those affected in folding, trafficking
or transport function per se (Valdez-Taubas et al., 2004; Vlanti
et al., 2006; Pantazopoulou et al., 2007). Using basically these
four tools, dozens of UapA mutations or chimeric molecules
have been characterized at the level of protein expression, stabil-
ity, sorting and turnover, as well as, of function and specificity.
In addition, using standard transport competition assays with
a plethora of purine or pyrimidine analogs, an extended sub-
strate binding specificity profile of UapA has been obtained.
These purely genetic, biochemical and kinetic approaches led to
a number of significant conclusions concerning specific amino
acid residues that are involved in substrate binding or/and trans-
port (see Figure 3). Among functionally important amino acid
residues, Glu356 and Gln408 were proposed to interact directly
with UapA substrates through H bonding implicating their polar
side chains, whereas seven more residues proved critical for sub-
strate translocation (see legend of Figure 3 and Diallinas et al.,
1998; Meintanis et al., 2000; Koukaki et al., 2005; Papageorgiou
et al., 2008a). These conclusions were strongly supported when
the firstmodeled structure of UapA became feasible (Amillis et al.,
2011; Kosti et al., 2012), immediately after the publication of the
crystal structure of a bacterial homolog, namely the UraA uracil
permease of E. coli (Lu et al., 2011). The structural model of UapA
and subsequent docking andMD approaches showed that amajor
xanthine binding site is formed by four specific residues in TMS3
(Phe155), TMS8 (Glu356) and TMS10 (Ala407 and Gln 408). The
same residues were shown to bind xanthine in the homologous
E. coliXanQ permease (Karatza et al., 2006; Karena and Frillingos,
2009, 2011; Georgopoulou et al., 2010; Mermelekas et al., 2010).
Importantly, the work on UapA has shown that reverse genetics
and biochemical approaches in a eukaryotic model system, sim-
ilarly to work performed in E. coli, constitute unique tools not
only for understanding the function of transporters, but also to
validate structural models emerging from homology modeling
approaches with available crystal structures.
Interestingly, in the course of extensive genetic and biochemi-
cal analyses of rationally designed mutants of UapA, no mutant
was obtained that altered significantly the specificity of UapA.
In other words, none of the UapA mutants studied acquired the
capacity to transport other nucleobases, such as adenine, gua-
nine, hypoxanthine or pyrimidines, which are all structurally
similar to the transporter physiological substrates, xanthine or
uric acid. This somehow contradicted the observation that sev-
eral among the functional mutations did modify the affinity for
xanthine, uric acid or some of their analogs, suggesting that these
mutations have modified the substrate binding site of UapA. The
single exception among the mutations characterized in respect to
UapA substrate specificity was Gln408Glu, a mutation replacing a
residue proposed to interact directly with substrates. Gln408Glu
was a crysosenstive mutation which at the permissive tempera-
ture led to moderate binding of hypoxanthine or guanine, but still
could not lead to detectable UapA-mediated transport of these
purines (Meintanis et al., 2000; Koukaki et al., 2005). The lack
of a UapA mutant capable of binding and transporting hypox-
anthine, or any other purine that is not uric acid and xanthine,
was a surprise. Hypoxanthine is smaller than xanthine and very
similar in structure, so how does UapA select between these two
purines? Or how can UapA distinguish between allopurinol and
hypoxanthine in favor of the former (Diallinas, 2013), given that
allopurinol and hypoxanthine are also very similar in structure?
These questions already suggested that transporter specificity
might not simply be determined by interactions within a freely
accessible major substrate binding site, but might rather depend
on complex inter-domain synergistic interactions, which proba-
bly underlie a transport mechanism more sophisticated than that
described in the originally proposed rocker-switch model.
In an attempt to suppress the cryosensitivity of the Gln408Glu
mutant, a second-site suppressor, Phe528Ser, was identified
within TMS14 of UapA (Amillis et al., 2001; note that in the orig-
inal article UapA was thought to have 12 TMSs, so Phe528Ser
was originally placed in TMS12). Subsequent kinetic analysis
of systematic site-directed replacements of Phe528 revealed that
substitution of Phe with small, aliphatic, amino acids led to trans-
porter molecules that could catalyze the transport of a series
of purines, albeit with low affinity (>1mM), without affecting
the high-affinity (5–10μM) for the physiological substrates, uric
acid and xanthine (Vlanti et al., 2006). Subsequently, a different
genetic screen designed to obtain UapA mutants able to trans-
port adenine, revealed two more residues that could affect UapA
specificity in a similar way (Papageorgiou et al., 2008a). These
residues were the partially conserved Thr526 and the variable
Gln113, the first lying in TMS14 and the second in the putative
extracellular loop between TMS1 and TMS2. Finally, a different
direct selection scheme, using as the starting strain Phe528Ser,
led to the isolation of more mutants which could transport even
more efficiently hypoxanthine or adenine, but again the relevant
mutation had no significant effect on the kinetics of transport of
xanthine or uric acid (Kosti et al., 2010). The relevant mutations
concerned residues in TMS11 (Ala441), TMS12 (Val463, Ala469),
and TMS13 (R481). The position of functionally critical residues
in UapA is shown in Figure 3.
Thus, random direct or indirect genetic screens led to the
identification of several specificity mutations in UapA domains
(TMS1-TMS2 loop, TMS11, TMS12, TMS13, and TMS14) none
of which is part of the presumed substrate binding pocket,
which is made by residues in TMS3, TMS8, and TMS10. All
these specificity mutations enlarged the capacity of UapA to
transport purines, pyrimidines and bulky analogs of xanthine.
Most critically, none of the specificity mutations affected signif-
icantly the Km values of UapA for its natural substrates xan-
thine or uric acid. This last observation dismissed the possibility
that the specificity mutations have affected the basic architec-
ture of the UapA substrate-binding site. If they did, they would
be expected to affect the affinity constants for uric acid or
xanthine, as well. Based on this logic, we have proposed that
specificity mutations should map in domains acting as selective
filters of channel-like gates. In other words, UapA, and pos-
sibly other transporters, seems to contain selective genetically
distinguishable outward- and cytoplasm-facing gates that con-
trol the access or removal of substrates from a major substrate
binding pocket. Specificity mutations very probably loosen the
selective role of these gates, so that, non-physiological substrates
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FIGURE 3 | Topology of UapA residues critical for function and specificity.
Left, upper panel: Topology of residues critical for the function and transport
kinetics of UapA. All important residues map in TMS1, TMS3, TMS8, and
TMS10. Residues interacting directly with substrate (xanthine) are highlighted
as yellow stars (Ser155, Glu356, A407, and Gln408). Among those, Glu356 and
Gln408 interact with substrates through their side chains (further highlighted
with a black outline). These two residues are irreplaceable for function. In
green are residues (Ser154, Phe406, G411, Arg417) affecting the local
topology of neighboring substrate-binding residues. Mutations in these
residues can differentially affect the affinity for different substrates (e.g., uric
acid vs. xanthine). In blue are residues (Gln85, His86, Met151, Asp360,
Thr405, Asn409, Asn410, and Thr416) involved in dynamic interdomain
interactions between helices TMS1, TMS3, and TMS10 (e.g., Gln86-Thr416,
His86-Asn409, His86-Met151, Asp360-Asn410-Thr416). Mutations in these
residues, which are often cryosensitive, abolish or dramatically reduce
transport activity without affecting significantly substrate binding. Little is
known on the residues binding H+ ions, but a Glu356 and Asp360 are possible
candidates. Evidence for the above conclusions comes from functional assays
of a plethora of mutants using a set of >25 different purines or purine related
analogs, aswell as, docking andMD approaches. Amongmutations concerning
residues critical for determining the affinity (Km/i values) for physiological
substrates and ligands, only Gln408Glu shifts significantly the binding
specificity of UapA toward novel ligands (hypoxanthine, guanine, uracil).
Importantly however, even in this case, the mutated UapA cannot transport
the novel ligands. In other, words no mutation affecting the functioning of the
presumed substrate binding site modifies dramatically the specificity of UapA.
Left, lower panel: Topology of residues critical for determining the substrate
specificity of UapA. All important residues map in TMS11 (Ala441), TMS12
(Val463, Ala469), TMS13 (Arg481), TMS14 (T526, Phe528) and in the loop
linking TMS1-TMS2 (Gln113). In other words, all specificity important residues
are located in domains distinct from those involved in the functioning of the
major substrate binding site. A single exception is Phe406, which is located in
TMS10. The importance of these residues was recognized through the
functional analysis of randomly, directly or indirectly, selected mutants able to
grow on non-physiological UapA substrates (e.g., hypoxanthine or adenine).
Most critically, no mutation in the residues affecting UapA specificity has a
significant effect on the Km and Vm values of UapA for its physiological
substrates, strongly supporting the idea that none of these mutations
concerns a residue located in the major substrate-binding site. Among
specificity mutations, the most prominent effects were obtained with
mutations at Arg481, Thr526, and Phe528, highlighted with a black outline
(Amillis et al., 2001; Vlanti et al., 2006; Papageorgiou et al., 2008a; Kosti et al.,
2010). Right: Homology model of UapA built using the inward-facing crystal
structure of the bacterial UraA permease. The model shows the major
substrate binding site and a translocation pathway leading to the inside of the
cell (Kosti et al., 2012). The substrate (e.g., xanthine) binding position, located
in silico through docking and MD approaches, is highlighted in the insert on
the top left. The insert on the top right depicts a putative secondary binding
site, coincident with residues Thr526 and Phe528, located at an outward
presumed gate, as this was defined by genetic, docking and MD approaches.
A speculative inward-facing gate is also supported by mutations in Arg481.
Combinations of different gate mutations (e.g., Arg481Gly/Thr526Leu or
Arg481Gly/Phe528Ser), or gate and major binding site mutations (e.g.,
Arg481Gly/Gln408Glu, Thr526Leu/Gln408Glu, Thr526Met/Gln408Glu,
Phe528Ala/Gln408Glu, Phe528Ser/Phe406Ala), lead to UapA versions with
distinct transport activities and specificities, supporting the functional
independence of the two presumed gates and the major substrate binding
site (Papageorgiou et al., 2008a; Kosti et al., 2010, 2012; Amillis et al., 2011).
can “leak” toward or out of the major binding site. This idea
predicted that we might be able to convert UapA into a very
efficient hypoxanthine transporter if we combine specificity
mutations in the gates with mutations in the bona fidae sub-
strate binding pocket, or combine gate mutations that simul-
taneously loosen the outward and inward-facing gates. This
was in fact the case. Combinations of different gate mutations
(e.g., Arg481Gly/Thr526Leu or Arg481Gly/Phe528Ser), or gate
and major binding site mutations (e.g., Arg481Gly/Gln408Glu,
Thr526Leu/Gln408Glu, Thr526Met/Gln408Glu, Phe528Ala/Gl
n408Glu, Phe528Ser/Phe406Ala), led to UapA versions with
distinct transport activities and specificities, supporting the func-
tional independence of the two presumed gates and the major
substrate binding site (see Figure 3 and Papageorgiou et al.,
2008a; Kosti et al., 2010).
What is the lesson from the classical genetic approaches used
in UapA? No rational design would have predicted the role of the
presumed gate residues which affect substrate specificity as these,
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unlike residues in the major binding site, are not well conserved.
Why are these residues not well conserved? In fact, in the case of
the NAT (Nucleobase Ascorbate Transporters) family where UapA
belongs, there is no genetic evidence supporting the existence of
residues critical for substrate specificity in analogous domains
of the bacterial homologs. For example, in XanQ (xanthine per-
mease), mutations in Asn430 and Ile432, which correspond to
residues Thr526 and Phe528 in UapA, do not confer the ability
for transport of purines other than xanthine, in sharp contrast
with the case of the A. nidulans transporter (Papakostas et al.,
2008; Frillingos, 2012). The analogous XanQ mutations simply
moderately affect the affinity of xanthine binding and allow the
transport of some xanthine analogs with bulky groups. This in
turn might suggest that in XanQ the domain analogous to gate
domain in fungi (A. nidulans) seems to function as a substrate
filter rather than a selectivity gate.
Overall, it seems that the evolution of substrate selectivity gates
is a functional novelty that might have arisen independently in
different transporter families or in different members of the same
family. The reason for that might be connected with a specific
selective advantage related to the need for more dynamic control
of substrate binding and transport in eukaryotic cells (see also
later). The variability in the evolution of gating mechanisms is
most strongly supported by recent structural reports that show
that the closure and opening of gates seems to be elicited by dif-
ferent mechanisms and distinct molecular elements in different
transporters (see below). Finally, the evolution of gates seems to
have also affected how transporters are regulated at the level of
cellular expression, sorting, endocytosis and turnover, as will be
discussed later.
ARE GATES IN TRANSPORTERS SUBSTRATE-SELECTIVE?
Accumulating evidence mainly from crystal structures, but
also from biophysical (e.g., interspin-distance measurements
from double electron-electron Resonance, distance-dependent
quenching of Trp fluorescence), biochemical (site-directed alky-
lation) and homologymodeling approaches, supports directly the
existence of transiently open and occluded conformations of trans-
porters (Smirnova et al., 2007; Fang et al., 2009; Gao et al., 2009;
Shaikh and Tajkhorshid, 2010; Forrest et al., 2011; Kaback et al.,
2011; Zhao and Noskov, 2011; Jiang et al., 2012; Krishnamurthy
and Gouaux, 2012; Madej et al., 2012; Shi, 2013; Kumar et al.,
2014; Penmatsa and Gouaux, 2014; Stelzl et al., 2014; Valdés et al.,
2014). In the analyzed crystal structures (see Table 1), the open
states face either the cytoplasm or the extracellular space, and in
both cases seem to allow free access of substrates and ions into
a single major binding site, found relatively deep in the trans-
porter body. In some crystal structures substrates or ligands and
inhibitors have been found bound to partially open conforma-
tions of transporters, whereas in other transporters are “caught”
empty. In the fully occluded state, the major substrate and ion
binding site is occupied and seems inaccessible from either the
cytoplasm or the extracellular side. This is so because specific
domains, the gates, have closed around the trapped substrate and
ions. Despite the common steric occlusion of the substrate in
all transporters, the degree to which different transporters block
solvent accessibility to the binding pocket from the extracellular
and cytoplasmic sides varies (Table 1). The independence of the
gating process from the inward- to outward major conformation
transition is emphasized by the observation that the occluded
state might have either an outward- or an inward-facing direc-
tion, or for different transporters, we can conclude that there
must be at least 5 structurally distinct conformations, as shown
in Figure 2; outward-facing with extracellular gate open (cyto-
plasmic gate occluded), outward-facing with extracellular gate
occluded (cytoplasmic gate remains occluded), intermediate with
both gates occluded, inward-facing with gates occluded, inward-
facing with only cytoplasmic gate open.
Thus, evidence supports the following sequence of events dur-
ing transport catalysis. In an outward-facing conformation the
extracellular gate fluctuates between occluded and open states
allowing access of extracellular Na+ or H+. Binding of these
cations, probably at the extracellular gate or deeper into the major
substrate binding pocket, stabilizes the outward-facing open state,
creating a high-affinity substrate-binding site. Following sub-
strate and potentially additional ion binding, the extracellular
gate closes and this closure promotes a transition to the inter-
mediate or inward-facing occluded state. In contrast to the local
changes associated opening and closing of gates, the isomer-
ization between the outward- and inward-facing states involves
larger-scale conformational changes spread throughout the trans-
porter. This structural transition from outward- to inward-facing
does not seem to involve the same domain movements in all
transporters and further experimental and computational stud-
ies will be required to understand the movements associated with
the transport cycle in each transporter studied. In the inward-
facing state, the initial event triggering substrate release appears
to be the release of Na+ or H+ ions. Following release of the
symported cations, the open state of the intracellular gate is stabi-
lized, leading to release of further ions and substrate. The empty
inward-facing open transporter can then transit back outward-
facing state and, thereby, complete the transport cycle. This model
is predominantly based on the study of secondary active trans-
porters and whether it is applicable to passive facilitators is still
disputable (Naftalin, 2008, 2010).
As already highlighted above, recent evidence supports the
idea that Na+ binding affects the opening and closing of the
gates (Celik et al., 2008; Shi et al., 2008; Claxton et al., 2010;
Krishnamurthy and Gouaux, 2012). But is there any evidence
that substrates also have an effect on opening of gates? Are the
gates themselves substrate-selective or they just open and close
stochastically or in response to ion concentrations? To function as
independent selective elements, the gates should act as transient
secondary substrate binding sites. Alternatively, the gates might
simply function as size- or charge-depended selective filters, when
present in their open state. Recent ligand-binding experiments
and molecular-dynamics simulations in LeuT, the Aquifex aeoli-
cus amino acid/Na+ symporter which has been extensively used
as a paradigm for understanding structure-function relation-
ships in the Amino Acid-Polyamine-Organocation (APC) family,
have suggested that there is an additional secondary binding
site between the primary site and the bulk extracellular solution
(Nyola et al., 2010; Thomas et al., 2014). Simultaneous occu-
pancy of this secondary site seemed to trigger the intracellular
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Table 1 | Transporters with known structures caught at various conformations.
Substrate Organism Family TMS Fold Conformation
LacY Lactose H+
symporter
E. coli MFS 6+6 -outward/occluded [4OAA]






E. coli MFS 6+6 -inward/open [1PW4]
FucP Fucose H+
symporter
E. coli MFS 6+6 -outward/open [3O7Q]





MFS 6+6 -occluded [2XUT]
-inward/open [4APS]
Glut1 Glucose facilitator Human MFS 6+6 -inward-/open [4PYP]
PiPT Phosphate
transporter?
Piriformospora indica (fungus) MFS 6+6 -inward/occluded [4J05]
LeuT Amino acid Na+ (*)
symporter
Aquifex aeolicus APC 5+5 -outward/open
(blocked with Trp) [3F3A]
-outward/occluded (blocked with inhibitors) [2QEI],
[2QJU]
-outward/occluded (inhibitor binding at secondary
site on the gate) [3GJD]
-outward/open
(blocked with conformation-specific antibody) [3TT1]
-inward-open
(blocked with conformation-specific antibody) [3TT1]
AdiC Arginine:agmatine
antiporter
APC 5+5 Outward/open [3OB6] [3LRB] [3NCY]
Outward/ occluded [3L1L]








Pyrococcus horikoshii APC 5+5 -outward [1XFH]
-intermediate [3V8F]
-inward (cysteine cross-linking) [3KBC]
-inward/open [4P19]
UraA Uracil H+ (*)
symporter
E. coli NAT/NCS2 7+7 -inward-/occluded [3QE7]
Mhp1 Benzyl-Hydantoin
Na+ (*) symporter





Drosophila melanogaster SLC 6+6 -outward/open (blocked with inhibitor) [4M48]
CNT Uridine transporter Vibrio cholerae SLC 6+6 -inward/occluded [3TIJ]
The table includes the most prominent examples of transporter structures that helped in developing our ideas on how transport catalysis takes place at a molecular
mechanistic level. All shown examples can be found in http:// blanco.biomol.uci.edu/mpstruc/ . The PDB code is included in the table. (*) denotes that these
transporters are considered to be Na+ symporters based on crystallographic studies, but their prokaryotic origin suggest that they might well function as H+ sym-
porters. MFS, Major Facilitator Superfamily; APC, Amino Acid-Polyamine-Organocation family; NAT/NCS2, Nucleobase/Ascorbate Transporter or Nucleobase:Cation
Symporter-2 family; NCS1, Nucleobase:Cation Symporter-1 family; SLC, is the Solute carrier Transporter family. More information on transporter families is available
in http:// www .tcdb.org/ .
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release of substrate and sodium ions from the primary site. X-ray
diffraction studies of LeuT, by contrast, do not show binding of
either the substrate leucine or the substrate analog selenome-
thionine anywhere other than the primary binding site (Piscitelli
et al., 2010; Penmatsa and Gouaux, 2014). On the other hand,
LeuT complexed with tryptophan, which locks the transporter
in an outward-open conformation, does bind a second trypto-
phan molecule in close proximity to the external gate (Singh
et al., 2008). This site might be transiently occupied as substrates
move from the extracellular vestibule to the primary binding
site, when the transporter is in the outward-open conforma-
tion. In line with the existence of secondary binding sites in
gates, some tricyclic antidepressants (TCAs), which have been
reported to inhibit the human serotonin transporter SERT (an
homolog of LeuT), were shown by docking studies, to bind
in the predicted outward-facing gate, thus preventing further
conformational changes needed for progress of the transport
cycle (Gabrielsen et al., 2012). Moreover, crystal structures of a
genetically engineered LeuT, resembling human biogenic amine
transporter, showed that these inhibitors bind to the outward-
facing gate and thus lock the transporter in an outward-facing
open conformation (Wang et al., 2013). Related to these obser-
vations, TBOA (a bulky aspartate analog) binding in GltPh, an
APC glutamate transporter from Pyrococcus horikoshii, blocks the
closing of the external gate and inhibits the transporter (Crisman
et al., 2009). The observation that bulky substrate analogs act
as competitive inhibitors of transport by partially occupying
the outward-facing gate of the transporter is also supported by
substituted cysteine accessibility method (SCAM) assays for the
eukaryotic NSS homolog GAT1 (Omoto et al., 2012), as well as
the human glucose transporter hSGLT (Raja et al., 2012). Docking
studies in Glut1, the human MFS type glucose facilitator, have
also supported the existence of multiple substrate binding sites
along a substrate translocation trajectory, some of which map
close to putative outward- and inward-facing gates (Cunningham
et al., 2006; Cunningham and Naftalin, 2013). Finally, flexible
docking studies have shown a well-supported secondary binding
site of substrates in the genetically identified putative external gate
of UapA (Kosti et al., 2012). The importance of gates in substrate
selection is thus more than apparent for the development of new
rationally designed drugs.
ACTIVITY-DEPENDENT CONTROL OF TRANSPORTER
EXPRESSION AND TURNOVER
Recent evidence strongly suggests that eukaryotic cells can
directly “sense” the conformational status or the functioning of
a transporter and accordingly regulate its turnover and possibly
its membrane sorting. This idea is related to the discovery that
several transporters are down-regulated by ubiquitination, endo-
cytosis and vacuolar degradation in response to their transport
activity. In other words, transporters are rapidly internalized from
the plasmamembrane (PM) and sorted to the endocytic/vacuolar
pathway when cell grow in the presence of relevant substrates, but
remain stable in the PM for many hours in the absence of external
substrates. This phenomenon has been well studied in several fun-
gal amino acid or purine transporters (Séron et al., 1999; Lin et al.,
2008; Nikko et al., 2008; Nikko and Pelham, 2009; Gournas et al.,
2010; Cain and Kaiser, 2011; Karachaliou et al., 2013; Crapeau
et al., 2014), but also seems to occur in mammalians transporters
involved in neurotransmission (Saunders et al., 2000; Whitworth
and Quick, 2001; Chi and Reith, 2003; Melikian, 2004; Miranda
and Sorkin, 2007; Zahniser and Sorkin, 2009; Okuda et al., 2011).
Some yeast metal transporters are also down regulated either in
the presence or in the absence of substrates, but in these cases
turnover seems to be mostly via direct sorting from the Golgi to
the endosomal/vacuolar pathway (Liu et al., 2007; Sullivan et al.,
2007; Erpapazoglou et al., 2008).
The primary signal for substrate-elicited endocytic turnover of
transporters is generally believed to be the over-accumulation of
substrates at potential toxic levels. Transporter down-regulation
is thought to provide a feedback control mechanism against cell
poisoning form excess substrate. In this case, cellular levels of sub-
strates would control the steady state levels of relevant transporter
indirectly, through a yet unknown signaling pathway. However,
recent evidence is against this scenario and rather strongly sup-
ports the idea that specific transporter conformations associated
with an active transport cycle can be directly “read” by a mech-
anism, which elicits transporter ubiquitination and subsequently
internalization and turnover. According to thismodel, the fate of a
transporter at each transport cycle depends on its transition to an
ubiquitination/endocytosis-eliciting conformation. In this case,
a transporter can either perform a full transport cycle by going
all the way to the inward-facing open conformation releasing the
substrate, or trigger ubiquitination and endocytosis by persisting
for sufficient time in an intermediate conformational state. More
recent evidence suggests that the endocytosis-eliciting state is the
substrate-occluded conformation (see below).
The above conclusions are mostly based on work performed
with the UapA uric acid-xanthine transporter of A. nidulans
(Gournas et al., 2010; Karachaliou et al., 2013) and two amino
acid permeases, Gap1 and Can1, in S. cerevisiae (Cain and
Kaiser, 2011; Schothorst et al., 2013; Ghaddar et al., 2014; Van
Zeebroeck et al., 2014). In all three transporters, most inactive
alleles or transporter versions with normal Km but very low Vm
values are blocked for substrate-elicited endocytosis. Moreover,
in UapA, substrate analogs that are not transported (e.g., 3-
methylxanthine) or internally accumulated substrates due to
genetic mutations (e.g., uric acid accumulation in a null mutant
of uric acid oxidase), do not elicit endocytosis. Finally, UapA or
Can1 mutant versions with modified specificity undergo endo-
cytosis in the presence of all “novel” substrates. For example,
a UapA version (Gln408Glu/Thr526Leu) transporting efficiently
hypoxanthine, in addition its natural substrates uric acid or xan-
thine, is endocytosed by all three purines (Gournas et al., 2010).
Furthermore, a Can1 variant (Ser176Asn/Thr456Ser) converted
to a lysine-specific permease is endocytosed by lysine instead of
arginine (Ghaddar et al., 2014). These observations constituted
primary evidence that transport-activity is absolutely necessary
for endocytosis.
Interestingly however, in specific cases substrate-elicited
endocytosis could be uncoupled from transport. In UapA,
the hyperactive (increased transport rate) specificity mutant
Phe528Ala, which transports with increased rate all purines,
does not undergo substrate-elicited endocytosis. Similarly,
in Can1, the hyperactive mutant Thr456Ser also did not
undergo substrate-elicited endocytosis. In addition, in Can1,
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the inactivation of transport activity due to a mutation in
a residue critical for proton-coupling (Glu184Gln) did not
abolish substrate-elicited endocytosis. Uncoupling of transport-
activity from endocytosis was also shown in Gap1 using different
substrates or substrate analogs (Schothorst et al., 2013; Van
Zeebroeck et al., 2014). In particular, L-Lysine is transported by
Gap1 but, unlike most other substrates (e.g., all L-amino acids),
does not trigger endocytosis. In addition, two transported, non-
metabolizable analogs, β-alanine and D-histidine, are strong and
weak elicitors of Gap1 endocytosis. Thus, mechanistically nei-
ther the completion of the transport cycle is a prerequisite for
endocytosis, nor the block of the transporter cycle necessarily
abolishes endocytosis. What seems to be necessary for endocy-
tosis to occur is a specific intermediate transporter conformation,
probably in a substrate-occluded state, persisting for a sufficient
period of time. The acquisition of this intermediate transporter
conformationmight not be hindered by specificmutations, which
however might be essential for subsequent steps necessary for
transport. In this model, it is also reasonable to propose that the
conformational change undergone by a transporter upon sub-
strate binding would lead to a significant rearrangement on its
cytosolic side and thus promote its recognition by the ubiquiti-
nation/endocytosis machinery. The model also suggests that to be
efficiently endocytosed a transporter must remain “long enough”
in the conformation recognized by this machinery.
Interestingly, some of the specificity mutations blocking
substrate-elicited endocytosis in UapA, as for example Phe528Ser,
map in the presumed external gate (Kosti et al., 2012). Notably,
UapA-Phe528Ser is a fully functional transporter with normal
Km values and increased transport rate, apparently due to the
loosening of its external selective gate. This means that fine
modifications solely in the gatingmechanism can affect substrate-
elicited endocytosis. This in turn suggests that effects in the gating
mechanism have a downstream effect on the overall conforma-
tional dynamics of the transporter and the time persistence of
specific intermediate conformations.
Among the transporters rigorously shown to undergo
substrate-elicited endocytosis, Gap1 has been shown to have a
second, transport-independent, function. In particular, Gap1 can
transduce signaling of the PKA pathway in response to the pres-
ence external amino acids. This dual property of Gap1 has his-
torically established the term transceptor for transporters, which
can also function as receptors involved in signal transduction
pathways (Van Zeebroeck et al., 2009). In the case of Gap1, the
sensing function could be uncoupled from the transport activity
by screening for non-transporter amino acid analogs that elicit
endocytosis, or transported analogs that do not trigger endocy-
tosis (Van Zeebroeck et al., 2009; Schothorst et al., 2013; Van
Zeebroeck et al., 2014). These observations indicate that signal-
ing, similarly to endocytosis, requires a ligand-induced specific
conformational change that may be part of, but does not neces-
sarily require the completion of the transport cycle. Interestingly,
endocytosis is not a prerequisite for signaling as these two phe-
nomena can also be uncoupled (Van Zeebroeck et al., 2014).
Overall, results with UapA, Gap1, and Can1 support the
concept that different substrates or ligands bind, probably to
partially overlapping binding sites or with distinct orientations
in a major substrate-binding pocket in transporters, triggering
divergent conformational dynamics which eventually result in
different conformation-induced downstream processes.
ATYPICAL TRANSPORTER FUNCTION: THE CASE OF
ALLOPURINOL TRANSPORT BY UAPA
The existence of gates in transporters does not violate the cur-
rently accepted model of the alternating access mechanism. It
rather adds a further degree of complexity, related to how sub-
strate specificity is determined by inter-domain synergy between
the gates and a major binding site. However, alternative mech-
anisms on how transporters function have also been proposed.
The most provocative of these models states that substrates
“slide down” through several docking points in a channel-like
trajectory, rather than inducing abrupt alternating conforma-
tional changes exposing a single major substrate binding site
extra- or intracellularly (Naftalin, 2008, 2010). This model is
mostly supported through docking studies and thermodynamic
approaches performed with specific facilitators, but also gains
genetic support in cases where mutations mapping outside the
major substrate-binding site modify substrate specificity. In addi-
tion, in some cases some transporters do not seem to follow
the typical Michaelis-Menten kinetic behavior, compatible with
a single substrate-binding site. This review does not intend to
extensively describe cases of transporter atypical behavior (for
this see the review Conde et al., 2010). It rather attempts to high-
light selected cases that might provoke, at least in specific cases,
the re-evaluation of the mechanism of transporter action in rela-
tion to drug uptake or efflux. One such case concerns the uptake
of allopurinol by A. nidulans.
Allopurinol is a structural isomer of hypoxanthine (4-
hydroxy[3,4-d]-pyrimidine) which acts as substrate and
non-competitive inhibitor of xanthine oxidase/dehydrogenase
(XO/XDH), a key enzyme for purine catabolism (Lewis et al.,
1978; Pacher et al., 2006). Through its inhibitory activity
on XO/XDH, allopurinol blocks uric acid production and is
thus used for gout treatment (reviewed in Lipkowitz, 2012).
Importantly, allopurinol has been used to treat Leishmania
infections and also displays activity against the related parasite
Trypanosoma brucei (de Koning and Jarvis, 1997; Natto et al.,
2005; Mishra et al., 2007). In contrast to other antiprotozoan
drugs, which are associated with severe side effects and emerging
resistance, allopurinol either alone or in combination with
other drugs, has proved to be more effective against cutaneous
infections. Consequently, transporters specific for allopurinol
have been identified at the molecular level in Leishmania and
Trypanosoma species. All known protozoan transporters are high
affinity (μM range) H+ symporters and exhibit a rather broad
specificity for most purines, pyrimidines and several analogs
(de Koning and Jarvis, 1997; Al-Salabi et al., 2003; Burchmore
et al., 2003; de Koning et al., 2004; Al-Salabi and de Koning,
2005; Natto et al., 2005). Interestingly, allopurinol has not been
used as an antifungal or antibacterial agent. In fungi, allopurinol
uptake has only been studied in A. nidulans, where genetic and
physiological evidence confirmed that UapA is the major gateway
for high-affinity, low-capacity, allopurinol uptake (Scazzocchio
et al., 1973; Diallinas and Scazzocchio, 1989). Interestingly
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however, in the course of identifying the transport mechanism
of allopurinol transport, two unexpected kinetic observations
became apparent; first, UapA-mediated radiolabeled allopurinol
transport is non-saturable and H+ gradient independent, and
secondly, the uptake of radiolabeled xanthine, rather than being
inhibited, as expected, by excess allopurinol, it is stimulated
(Diallinas, 2013). The effect of allopurinol on xanthine uptake
was not reciprocal, as excess xanthine or other substrates of
UapA inhibit allopurinol uptake. In addition, flexible docking
approaches failed to detect allopurinol binding in the major
UapA substrate binding site. Although the stimulating effect of
allopurinol on xanthine transport could, in principle, be ratio-
nalized by a cryptic allopurinol-specific allosteric site, evidence
was obtained supporting that accelerated influx of xanthine is
triggered through exchange with cytoplasmically accumulated
allopurinol. Further kinetic experiments strongly suggested that
allopurinol is transported by facilitated diffusion through a
substrate translocation trajectory, which is distinct from, but
probably overlapping with, that of physiological UapA substrates
(Diallinas, 2013).
The atypical phenomenon underlying allopurinol transport
by UapA was rationalized by the existence of substrate-specific
alternative mechanisms and partially overlapping translocation
trajectories in a single transporter. Interestingly, the existence of
alternative and partially overlapping substrate trajectories has also
been shown in the mammalian glucose transporter GLUT1 (Jiang
et al., 2010). The message from these studies is that transporter-
dependent cellular uptake or efflux of drugs might not show the
typical kinetic behavior expected, and in these cases more rig-
orous biochemical or genetic approaches should be performed
to understand the mechanism behind the phenomenon. On the
other hand, the atypical behavior of a transporter might also
become an advantage, especially when combination or cocktails
of drugs is used, as the presence of a substrate might stimulate the
translocation of another, the latter being the one with cytotoxic
activity.
CONCLUSIONS
Transporters, despite their proven role in drug uptake and efflux,
have been little exploited toward this direction, obviously due to
the significant lack of knowledge concerning their function, speci-
ficity and regulation of expression. Currently nearly 70 bona fidae
transporter crystal structures are known, of which less than 50
concern secondary active transporters, facilitators or antiporters,
and only 4 of them are of eukaryotic origin. Bacterial transporter
structures are used quite successfully to model human homologs,
but this approach risks erroneous or overstated conclusions.
This is so because bacterial transporters are usually smaller in
length due to much shorter N- or C- terminal regions, or inter-
nal hydrophilic loops, which in eukaryotes have been shown to
be extremely critical for transporter function, specificity, cel-
lular sorting and turnover. In addition, several of the known
prokaryotic structures correspond to transporters of unknown
physiological function, specificity and regulation, simply because
these proteins proved more stable for crystallography.
The lack of knowledge on transporters, especially those of
eukaryotes, is obviously due to general technical difficulties
associated with their transmembrane nature, but also due to
limited use of appropriate genetic or other alternative approaches
to structural biology. In this review, I selected to present some
paradigmatic genetic studies on fungal transporters, which led
and continue to lead to novel knowledge on transporter function
and regulation. In my opinion, one of the most prominent recent
discoveries on transporter function is the existence of channel-
like gates. Their existence was indeed predicted using rigorous
genetic and biochemical approaches, before crystals became avail-
able and confirmed their presence. A second novel finding is
related to substrate-elicited endocytosis and in particular to the
idea that eukaryotic cells directly sense transporter function and
accordingly regulate their turnover in order to achieve cell home-
ostasis to specific physiological, developmental or stress condi-
tions. Impressively, what has been found on fungal transporter
substrate-elicited endocytosis seems to hold true for mammalian
transporters involved in neurotransmission. Finally, I gave an
example, using a fungal transporter, but also discussing a similar
case in a human transporter, on how transporters can, in some
cases, show atypical kinetic behavior.
In summary, I think we need to learn much more on trans-
porter function and regulation before we use them as tools
in drug action. Recent crystal structures of mostly prokaryotic
transporters and recent functional and computational studies of
eukaryotic homologs have generated hypotheses on how trans-
porters accomplish solute uptake. However, not all states in the
transporter cycles have yet been identified in transporters, and
only 4 crystal structures are available for eukaryotic transporters.
More crystal structures might help in solving these controversies.
In addition, many of the states proposed from existing crystal
structures still need to be verified by other methods. To obtain
new knowledge we definitely need to use appropriate eukaryotic
model systems and interdisciplinary approaches, including func-
tional genomics, reverse genetics, easy transport assays, in vivo
microscopy, rational and random genetic screens, in addition to
crystallography and other biophysical approaches. Knowledge of
the different states in the transporter cycles at a molecular level
will eventually assist in developing new highly targeted drugs.
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